董事会认为，本公司与无忧健康签署战略合作备忘录，可将本集团的大健康业务深化，加强本集团的竞 争力，提升本集团的财务表现及盈利能力，符合本公司及其股东的整体利益。 于订立战略合作备忘录后，双方将就社区大健康服务平台及其服务内容方面开展相关的市场分析、行业 研究，并会尽快开始人员沟通及实地考察工作，包括但不限于健康平台的选址、服务内容、管理人员安 排、选品或开发新产品的规划等。 中国健康科技集团(01069)发布公告，于2025年9月26日，本公司与无忧健康(控股)集团有限公司(无忧健 康)订立不具法律效力及约束力的战略合作备忘录(战略合作备忘录)，根据战略合作备忘录，双方同意开 展有关社区大健康服务平台建设及大健康产品开发与销售方面的合作(合作业务)。 根据战略合作备忘录，本公司拟通过无忧健康的的市场优势及大健康产品，共同在中国健康产业探讨合 作机遇，促进本集团大健康产业发展，开发和销售业务板块，拓展未来业务多样性和提升未来的利润增 长点。同时，本集团亦可以通过自有的大健康品牌与无忧健康共同开发大健康产品，利用市场管道促进 合作业务的推广及销售。 ...

Group 1 - The core viewpoint of the article highlights the opportunities for the health consumption sector in China due to the aging population and supportive government policies, as outlined in the "Action Plan for Promoting Healthy Consumption" released by 12 departments including the Ministry of Commerce and the National Health Commission [1] - The discussion at the "European Forum" in Paris emphasized the rapid development of China's medical innovation sector and the unique opportunities for Sino-European cooperation in healthcare, as stated by former French Health Minister Olivier Véran [1][3] - Véran noted that cooperation between China and Europe could lead to both regions becoming long-term partners and global leaders in healthcare, with China needing access to European markets and Europe seeking to deepen connections with Chinese innovation resources [1][3] Group 2 - Olivier Dessajan, CEO of High Life China and President of the French Health Industry Alliance, expressed the importance of collaboration with China, stating that not engaging with China would be a mistake [3] - The establishment of high-end medical service nursing homes in cities like Guangzhou, Hangzhou, and Shenzhen by High Life China reflects the adaptation to local regulations while incorporating French operational mechanisms [3] - The CEO of Pro Pharma, Zhu Fangmeng, emphasized the significance of Sino-European cooperation in innovation and manufacturing, noting that nearly one-third of their overseas market is in Europe [3] Group 3 - The discussion highlighted the advanced technologies available in France and Europe, such as confocal endoscopy and radiofrequency ablation devices, while China leads in AI-assisted treatments and clinical trial results [4] - Véran pointed out the important reforms China has made to facilitate the entry of biopharmaceutical companies into the European market, particularly in modernizing drug regulations and accelerating clinical trials [4] - The strategy for AI application in healthcare should balance caution and innovation to promote harmonious economic relations and public interest between China and Europe, according to Véran [4]